{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:30Z","timestamp":1740149010068,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004358","name":"Samsung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12325-022-02404-x","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T03:02:57Z","timestamp":1673319777000},"page":"1047-1061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea"],"prefix":"10.1007","volume":"40","author":[{"given":"Dong W.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geuntae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae H.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongmin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong H.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younjin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wooree","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2307-8575","authenticated-orcid":false,"given":"Dong I.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"2404_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14712598.2021.1958778","volume":"22","author":"FS Macaluso","year":"2022","unstructured":"Macaluso FS, Cummings JF, Atreya R, Choi J, Orlando A. A systematic review on infliximab biosimilar SB2: from pre-clinical data to real-world evidence. Expert Opin Biol Ther. 2022;22:203\u201323.","journal-title":"Expert Opin Biol Ther"},{"key":"2404_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1517\/14656566.2.6.1015","volume":"2","author":"E Valle","year":"2001","unstructured":"Valle E, Gross M, Bickston SJ. Infliximab. Expert Opin Pharmacother. 2001;2:1015\u201325.","journal-title":"Expert Opin Pharmacother"},{"key":"2404_CR3","unstructured":"Janssen Biologics. Remicade - Prescribing information 1998 [Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/REMICADE-pi.pdf."},{"key":"2404_CR4","unstructured":"Janssen Biologics. Remicade - Summary of Product Characterisitcs 1999 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf."},{"key":"2404_CR5","first-page":"139","volume":"13","author":"R Melsheimer","year":"2019","unstructured":"Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade(\u00ae) (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139\u201378.","journal-title":"Biologics"},{"key":"2404_CR6","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies\u2014non-clinical and clinical issues 2012 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similarbiological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf."},{"key":"2404_CR7","unstructured":"US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product 2015 https:\/\/www.fda.gov\/media\/82647\/download."},{"key":"2404_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","volume":"80","author":"H Kim","year":"2020","unstructured":"Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80:99\u2013113.","journal-title":"Drugs"},{"key":"2404_CR9","unstructured":"Ministry of Food and Drug Safety. Safety Control after Releasing Medicinal Products etc. - Guideline on re-examination affairs of new drugs etc. 2018 https:\/\/www.mfds.go.kr\/eng\/brd\/m_18\/down.do?brd_id=eng0003&seq=71469&data_tp=A&file_seq=1."},{"key":"2404_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"JY Choe","year":"2017","unstructured":"Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58\u201364.","journal-title":"Ann Rheum Dis"},{"key":"2404_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/ibd\/izaa036","volume":"27","author":"FS Macaluso","year":"2021","unstructured":"Macaluso FS, Fries W, Viola A, et al. The SPOSIB SB2 sicilian cohort: safety and effectiveness of infliximab biosimilar sb2 in inflammatory bowel diseases. Including Multiple Switches Inflamm Bowel Dis. 2021;27:182\u20139.","journal-title":"Including Multiple Switches Inflamm Bowel Dis"},{"key":"2404_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/cts.13131","volume":"15","author":"S Mazza","year":"2022","unstructured":"Mazza S, Piazza OSN, Conforti FS, et al. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Clin Transl Sci. 2022;15:172\u201381.","journal-title":"Clin Transl Sci"},{"key":"2404_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/annrheumdis-2021-eular.1642","volume":"80","author":"B Fautrel","year":"2021","unstructured":"Fautrel B, Bouhnik Y, Dougados M, Freudensprung U, Addison J. PERFUSE: A French prospective\/retrospective noninterventional cohort study of infliximab-na\u00efve and transitioned patients receiving infliximab biosimilar SB2; 12-month analysis. Ann Rheum Dis. 2021;80:544.","journal-title":"Ann Rheum Dis"},{"key":"2404_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/MEG.0000000000001988","volume":"32","author":"R Lovero","year":"2021","unstructured":"Lovero R, Losurdo G, La Fortezza RF, et al. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021;32:201\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2404_CR15","doi-asserted-by":"publisher","first-page":"175628482098280","DOI":"10.1177\/1756284820982802","volume":"14","author":"S Fischer","year":"2021","unstructured":"Fischer S, Cohnen S, Klenske E, et al. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therap Adv Gastroenterol. 2021;14:1756284820982802.","journal-title":"Therap Adv Gastroenterol."},{"key":"2404_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3899\/jrheum.140538","volume":"42","author":"D Choquette","year":"2015","unstructured":"Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F. Incidence and management of infusion reactions to infliximab in a prospective real-world community registry. J Rheumatol. 2015;42:1105\u201311.","journal-title":"J Rheumatol"},{"key":"2404_CR17","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/acr.22096","volume":"65","author":"MV Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez MV, Sanmart\u00ed R, Ca\u00f1ete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013;65:2024\u201331.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2404_CR18","first-page":"680","volume":"11","author":"G D'Haens","year":"2017","unstructured":"D\u2019Haens G, Reinisch W, Colombel JF, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn\u2019s Disease treated with infliximab [Remicade\u00ae] or conventional therapy. J Crohns Colitis. 2017;11:680\u20139.","journal-title":"J Crohns Colitis"},{"key":"2404_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry. Am J Gastroenterol. 2012;107:1409\u201322.","journal-title":"Am J Gastroenterol"},{"key":"2404_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jbspin.2006.03.008","volume":"74","author":"V Ducoulombier","year":"2007","unstructured":"Ducoulombier V, Solau E, Coquerelle P, et al. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. Joint Bone Spine. 2007;74:56\u20139.","journal-title":"Joint Bone Spine"},{"key":"2404_CR21","first-page":"959","volume":"29","author":"WP Maksymowych","year":"2002","unstructured":"Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002;29:959\u201365.","journal-title":"J Rheumatol"},{"key":"2404_CR22","doi-asserted-by":"publisher","first-page":"204062232110419","DOI":"10.1177\/20406223211041927","volume":"12","author":"S Yang","year":"2021","unstructured":"Yang S, Yang S, Kwon Jo Y, et al. Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:20406223211041930.","journal-title":"Ther Adv Chronic Dis."},{"key":"2404_CR23","first-page":"E140","volume":"64","author":"T Otsuka","year":"2018","unstructured":"Otsuka T, Ooi M, Tobimatsu K, et al. Short-term and long-term outcomes of infliximab and tacrolimus treatment for moderate to severe ulcerative colitis: retrospective observational study. Kobe J Med Sci. 2018;64:E140\u20138.","journal-title":"Kobe J Med Sci"},{"key":"2404_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1471-230X-9-66","volume":"9","author":"P Miheller","year":"2009","unstructured":"Miheller P, Lakatos PL, Horv\u00e1th G, et al. Efficacy and safety of infliximab induction therapy in Crohn\u2019s Disease in Central Europe\u2013a Hungarian nationwide observational study. BMC Gastroenterol. 2009;9:66.","journal-title":"BMC Gastroenterol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02404-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02404-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02404-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:26:09Z","timestamp":1678087569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02404-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2404"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02404-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"13 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}